ArticleScientific reports2018
β-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 99 citations in OpenAlex.
- High-throughput identification of bacterial β-glucuronidase inhibitors using machine learning.Gut microbes · 2026Article
- The Effect of the Duration of Feeding a Diet Containing Cuban Cricket (Animals : an open access journal from MDPI · 2026Article
- Ingestible probes for breath-based monitoring of drug-metabolizing activity from the microbiome.Science advances · 2026Article
- Global metabolomics profiling of glucuronides in human plasma, fecal, and cerebrospinal fluid samples.Analytical and bioanalytical chemistry · 2026Article
- Glucuronidation metabolomic fingerprinting to map host-microbe metabolism.Nature communications · 2026Article
- Menopause-associated gut microbiome remodeling and pharmacomicrobiomics: emerging mechanisms influencing drug response.Frontiers in microbiomes · 2026Review
- Butyrate prevents chemotherapy-induced gastrointestinal toxicity and microbial dysbiosis.Scientific reports · 2025Article
- Characterization of fecal deglucuronidation activity in healthy subjects and in patients treated with fecal microbiota transplantation.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Butyrate Modulates Intestinal Microbiome and Epithelial Function to Attenuate Irinotecan-induced GI Toxicity.Research square · 2025Article
- The role of the gut microbiota in chemotherapy response, efficacy and toxicity: a systematic review.NPJ precision oncology · 2025Article
- A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability.iScience · 2025Article
- Synthetic β-d-Glucuronides: Substrates for Exploring Glucuronide Degradation by Human Gut Bacteria.ACS omega · 2025Article
- Action and immunomodulatory mechanisms, formulations, and safety concerns of probiotics.Bioscience of microbiota, food and health · 2025Review
- The role of gut microbial β-glucuronidases in carcinogenesis and cancer treatment: a scoping review.Journal of cancer research and clinical oncology · 2024Article
- Advanced piperazine-containing inhibitors target microbial β-glucuronidases linked to gut toxicity.RSC chemical biology · 2024Article
- Article
- Article
- Microbial β-Glucuronidase Hydrogel Beads Activate Chemotherapeutic Prodrug.ACS applied materials & interfaces · 2024Article
- Cancer invasion and anaerobic bacteria: new insights into mechanisms.Journal of medical microbiology · 2024Review
- Integrating the gut microbiome and pharmacology.Science translational medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut bacterial β-D-glucuronidases (GUSs) catalyze the removal of glucuronic acid from liver-produced β-D-glucuronides. These reactions can have deleterious consequences when they reverse xenobiotic metabolism. The human gut contains hundreds of GUSs of variable sequences and structures. To understand how any particular bacterial GUS(s) contributes to global GUS activity and affects human health, the individual substrate preference(s) must be known. Herein, we report that representative GUSs vary in their ability to produce various xenobiotics from their respective glucuronides. To attempt to explain the distinct substrate preference, we solved the structure of a bacterial GUS complexed with coumarin-3-β-D-glucuronide. Comparisons of this structure with other GUS structures identified differences in loop 3 (or the α2-helix loop) and loop 5 at the aglycone-binding site, where differences in their conformations, hydrophobicities and flexibilities appear to underlie the distinct substrate preference(s) of the GUSs. Additional sequence, structural and functional analysis indicated that several groups of functionally related gut bacterial GUSs exist. Our results pinpoint opportunistic gut bacterial GUSs as those that cause xenobiotic-induced toxicity. We propose a structure-activity relationship that should allow both the prediction of the functional roles of GUSs and the design of selective inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.